To the investigative team of Vladwood and Zebstein:
Have you considered tracking the movements of Paine Webber accounts in VVUS from Monday to Friday last week?
Here is a summary of the VVUS price action and milestones for your background:
BigKNY3
Date.......Shares.......High....Low..........Close
07/02/98..642,000.......6 ......5 3/4.......5 13/16
07/06/98..1,827,500.....7 1/4...5 13/16.....6 7/8
07/07/98..8,244,600.....10......7 3/4.......10
07/08/98..5,190,900.....10 1/4...8 1/2......9 3/16
07/09/98..3,272,200.....8 13/16...7 5/8.....7 3/4
07/10/98..5,875,200.....6 15/16...6 1/4 .....6 1/2
Monday: VVUS raises on heavy volume on no news and flat Rxs
Tuesday: Paine Webber ( a market maker for VVUS) issues an upgrade to buy from neutral. www3.techstocks.com
1. We are raising our rating on the shares of Vivus* to buy from
neutral, reflecting what we believe to be the beginnings of a turn in
new prescriptions and recent FDA approval for domestic shipments from
its new 90,000 square-foot manufacturing facility.
2. Moreover, we sense that the company may be on the verge of announcing plans to dramatically reduce costs and even restructure its sales organization.
3. If domestic demand rebounds as we are forecasting and costs trend
lower, we believe that Vivus can deliver earnings per share of $1.00
next year. Were this dramatic a turnaround to occur, VVUS could, we
think, reach $20 within a year.
Wednesday (After the close): VVUS issues restructuring press release
Thursday(After the close): VVUS issues earnings report and conducts conference call. |
